systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-355Research ArticleОБЗОРЫПроблема определения эффективности вмешательств в эпоху доказательной медицины: мировой и отечественный опытThe problem of determining the efficiency of treatmentin the era of evidence-based medicine: international and domestic experienceГиляревскийС. Р.GilyarevskyS. R.noemail@neicon.ruГБОУ ДПО РМАПО Минздрава России; НИИ скорой помощи им. Н.В.Склифосовского, МоскваРоссия2014231220221126771Copyright © Гиляревский С.Р., 20222022Гиляревский С.Р.Gilyarevsky S.R.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/355

В статье обсуждаются современные подходы к выбору эффективных средств для профилактики осложнений сердечно-сосудистых заболеваний, включая ингибиторы ангиотензинпревращающего фермента и блокаторы рецепторов ангиотензина II. Рассматриваются доказательные основы применения таких средств и принципы определения эффективной терапии в определенных клинических ситуациях. Приводятся данные не только рандомизированных клинических исследований, но и относительно недавно полученные результаты обсервационных исследований, отражающих реальную практику применения антигипертензивных средств.

This article deals with the modern approach to the choice of effective drugs, such as angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, in preventing cardiovascular complications. We discuss evidential considerations of the drugs administration and the detection principles, concerning effective therapy in special clinical situations. The present paper deals with the results not only of the randomized trials but with the results from recent observational studies being reflective of real practice in the application of antihypertensive drug.

артериальная гипертензияингибиторы ангиотензинпревращающего ферментаблокаторы рецепторов ангиотензинаarterial hypertensionangiotensin-converting enzyme inhibitorsangiotensin receptor blockersReferencesВерткин А.Л., Скотников А.С. Клинико - фармакологические ниши сартанов в терапии коморбидных больных. Клин. фармакология 2013; 2. Availableat: www.lvrach.ru/2013/02/15435637/Верткин А.Л., Скотников А.С. Клинико - фармакологические ниши сартанов в терапии коморбидных больных. Клин. фармакология 2013; 2. Availableat: www.lvrach.ru/2013/02/15435637/Savarese G, Costanzo P, Cleland J.G et al. A meta - analysis reporting effects of angiotensin - converting enzyme inhibitors and angiotensin receptor blockers in patients without heartfailure. J Am Coll Cardiol 2013; 61: 131-42.Savarese G, Costanzo P, Cleland J.G et al. A meta - analysis reporting effects of angiotensin - converting enzyme inhibitors and angiotensin receptor blockers in patients without heartfailure. J Am Coll Cardiol 2013; 61: 131-42.Moher D, Liberati A, Tetzlaff J, Altman D.G. PRISMA Group. Preferred reporting items for systematic reviews and meta - analyses: the PRISMA statement. J Clin Epidemiol 2009; 62: 1006-12.Moher D, Liberati A, Tetzlaff J, Altman D.G. PRISMA Group. Preferred reporting items for systematic reviews and meta - analyses: the PRISMA statement. J Clin Epidemiol 2009; 62: 1006-12.Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Forceforthe Managementof Arterial Hypertensionof the European Societyof Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159-219.Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Forceforthe Managementof Arterial Hypertensionof the European Societyof Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159-219.Law M.R, Morris J.K, Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta - analysis of 147 randomised trials in the contex to fexpectations from prospective epidemiological studies. BMJ 2009; 338: b1665.Law M.R, Morris J.K, Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta - analysis of 147 randomised trials in the contex to fexpectations from prospective epidemiological studies. BMJ 2009; 338: b1665.Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure - lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165: 1410-19.Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure - lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165: 1410-19.Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood - pressure - lowering regimens on major cardiovascular events: results of prospectively - designed overviews of randomized trials. Lancet 2003; 362: 1527-35.Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood - pressure - lowering regimens on major cardiovascular events: results of prospectively - designed overviews of randomized trials. Lancet 2003; 362: 1527-35.Chassin M.R. Is healthcare ready for Six Sigmaquality? Milbank Q 1998; 76: 510, 565-91.Chassin M.R. Is healthcare ready for Six Sigmaquality? Milbank Q 1998; 76: 510, 565-91.Mancia G. Role of outcome trials in providing information on antihypertensive treatment: importance and limitations. Am J Hypertens 2006; 19: 1-7.Mancia G. Role of outcome trials in providing information on antihypertensive treatment: importance and limitations. Am J Hypertens 2006; 19: 1-7.Woolf S.H, Grol R, Hutchinson A et al. Clinical guidelines: potential benefits, limitations, and harms ofclinical guidelines. BMJ 1999; 318: 527-30.Woolf S.H, Grol R, Hutchinson A et al. Clinical guidelines: potential benefits, limitations, and harms ofclinical guidelines. BMJ 1999; 318: 527-30.Zanchetti A. Evidence - based medicine in hypertension: what type of evidence? J Hypertens 2005; 23: 1113-20.Zanchetti A. Evidence - based medicine in hypertension: what type of evidence? J Hypertens 2005; 23: 1113-20.Cardinal H, Monfared A.A, Dorais M, Le Lorier J. A compare is on between persistence to therapy in ALLHAT and in every day clinical practice: a generaliz ability issue. Can J Cardiol 2004; 20: 417-21.Cardinal H, Monfared A.A, Dorais M, Le Lorier J. A compare is on between persistence to therapy in ALLHAT and in every day clinical practice: a generaliz ability issue. Can J Cardiol 2004; 20: 417-21.Craig P, Dieppe P, Macintyre S et al. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ 2008; 337: a1655.Craig P, Dieppe P, Macintyre S et al. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ 2008; 337: a1655.Hannan E.L. Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations. JACC Cardiovasc Int 2008; 1: 211-7.Hannan E.L. Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations. JACC Cardiovasc Int 2008; 1: 211-7.Ligthelm R.J, Borzi V, Gumprecht J et al. Importance of observational studies in clinical practice. Clin Ther 2007; 29 (Spec. No): 1284-92.Ligthelm R.J, Borzi V, Gumprecht J et al. Importance of observational studies in clinical practice. Clin Ther 2007; 29 (Spec. No): 1284-92.Bramlage P, Pittrow D, Kirch W. The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16,600 patients in primary care. Curr Med Res Opin 2004; 20: 1625-31.Bramlage P, Pittrow D, Kirch W. The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16,600 patients in primary care. Curr Med Res Opin 2004; 20: 1625-31.Bramlage P, Schonrock E, Odoj P. Metabolic effects of an AT1-receptor blockade combined with HCTZ in cardiacrisk patients: a non interventional study in primary care. BMC Cardiovasc Dis 2008; 8: 30.Bramlage P, Schonrock E, Odoj P. Metabolic effects of an AT1-receptor blockade combined with HCTZ in cardiacrisk patients: a non interventional study in primary care. BMC Cardiovasc Dis 2008; 8: 30.Kintscher U, Bramlage P, Paar W.D et al. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a subanalysis of the Treatto Targetpost authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc Diabetol 2007; 6: 12.Kintscher U, Bramlage P, Paar W.D et al. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a subanalysis of the Treatto Targetpost authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc Diabetol 2007; 6: 12.Mann R, Mackay F, Pearce G e tal. Losartan: a study of pharmacovigilance data on 14,522 patients. J Hum Hypertens 1999; 13: 551-7.Mann R, Mackay F, Pearce G e tal. Losartan: a study of pharmacovigilance data on 14,522 patients. J Hum Hypertens 1999; 13: 551-7.Morales-Olivas F.J, Aristegui I, Estan L et al. The KARTAN study: a postmarketing assessment of irbesartan in patients with hypertension. Clin Ther 2004; 26: 232-44.Morales-Olivas F.J, Aristegui I, Estan L et al. The KARTAN study: a postmarketing assessment of irbesartan in patients with hypertension. Clin Ther 2004; 26: 232-44.Robles N.R, Martin-Agueda B, Lopez-Munoz F, Alamo C. Effectiveness of eprosartan in diabetic hypertensive patients. Eur J Intern Med 2008; 19: 27-31.Robles N.R, Martin-Agueda B, Lopez-Munoz F, Alamo C. Effectiveness of eprosartan in diabetic hypertensive patients. Eur J Intern Med 2008; 19: 27-31.Strutz F, Bramlage P, Paar W.D. Effect of three months’ treatment with irbesartan on blood and pulse pressure of hypertensive type 2 diabetic patients: open, observational study in 31,793 patients. Curr Med Res Opin 2005; 21: 1433-40.Strutz F, Bramlage P, Paar W.D. Effect of three months’ treatment with irbesartan on blood and pulse pressure of hypertensive type 2 diabetic patients: open, observational study in 31,793 patients. Curr Med Res Opin 2005; 21: 1433-40.Sharplin P, Beckham C, Televantou F, Chamberlain G. Early vs. late usage of angiotensin receptor blockers in the antihypertensive treatment pathway. Presnted at American Society of Hypertension; May 14-17, 2008; New Orleans, LA.Sharplin P, Beckham C, Televantou F, Chamberlain G. Early vs. late usage of angiotensin receptor blockers in the antihypertensive treatment pathway. Presnted at American Society of Hypertension; May 14-17, 2008; New Orleans, LA.Sharplin P, Beckham C, Televantou F, Chamberlain G. An analysis of the antihypertensive effectiveness of ARBsvs. ACE inhibitors. Presented at International Society for Pharmacoeconomics and Outcomes Research; November 8-11, 2008; Athens, Greece.Sharplin P, Beckham C, Televantou F, Chamberlain G. An analysis of the antihypertensive effectiveness of ARBsvs. ACE inhibitors. Presented at International Society for Pharmacoeconomics and Outcomes Research; November 8-11, 2008; Athens, Greece.Sharplin P, Chamberlain G, Beckham C, Wisniacki N. Antihypertensive effect of angiotensin receptor blockers vs. other classes of antihypertensives in UK primary care. Presented at American College of Cardiology; March 29 - April 1, 2008; Chicago, IL.Sharplin P, Chamberlain G, Beckham C, Wisniacki N. Antihypertensive effect of angiotensin receptor blockers vs. other classes of antihypertensives in UK primary care. Presented at American College of Cardiology; March 29 - April 1, 2008; Chicago, IL.Petrella R.J., Charki M. Ananalysis of the antihypertensive effectiveness of combination therapies containing ARBs versus ACE inhibitors. Presented at ISPOR 12th Annual European Congress; October 24-27, 2009; Paris, France. Poster PCV21.Petrella R.J., Charki M. Ananalysis of the antihypertensive effectiveness of combination therapies containing ARBs versus ACE inhibitors. Presented at ISPOR 12th Annual European Congress; October 24-27, 2009; Paris, France. Poster PCV21.Petrella R., Michailidis P. Retrospective analysis of real - world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management. Clin Ther 2011; 33: 1190-203.Petrella R., Michailidis P. Retrospective analysis of real - world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management. Clin Ther 2011; 33: 1190-203.Bobrie G, Delonca J, Moulin C et al. A home blood pressure monitoring study comparing the antihypertensive efficacy two angiotensin II receptor antagonist fixed combinations. Am J Hypertens 2005; 18: 1482-8.Bobrie G, Delonca J, Moulin C et al. A home blood pressure monitoring study comparing the antihypertensive efficacy two angiotensin II receptor antagonist fixed combinations. Am J Hypertens 2005; 18: 1482-8.Neutel J.M, Smith D. Ambulatory blood pressure comparison of the anti - hypertensive efficacy of fixed combinations of irbesartan/hydrochlorothiazide and losartan/hydrochlorothiazide in patients with mild - to - moderate hypertension. J Int Med Res 2005; 33: 620-31.Neutel J.M, Smith D. Ambulatory blood pressure comparison of the anti - hypertensive efficacy of fixed combinations of irbesartan/hydrochlorothiazide and losartan/hydrochlorothiazide in patients with mild - to - moderate hypertension. J Int Med Res 2005; 33: 620-31.

The authors declare that there are no conflicts of interest present.